Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine
→ Amgen has enlisted Hummingbird Bioscience on a new antibody discovery pact, turning over some novel targets to see if the smaller player’s “systems biology” platform can yield better therapeutics. Starting with two initial programs with the potential to add 10 more over the next six years, Amgen has exclusive options to license the resulting antibodies for $100 million per project. Hummingbird, which has offices in Houston, South San Francisco and Singapore, is also receiving an undisclosed upfront and research payments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.